Alzheimer's Institute of America v. Eli Lilly & Co.

128 F. Supp. 3d 1249, 2015 U.S. Dist. LEXIS 121078, 2015 WL 5243874
CourtDistrict Court, N.D. California
DecidedJune 5, 2015
DocketCase No. 10-cv-00482-EDL
StatusPublished
Cited by2 cases

This text of 128 F. Supp. 3d 1249 (Alzheimer's Institute of America v. Eli Lilly & Co.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Alzheimer's Institute of America v. Eli Lilly & Co., 128 F. Supp. 3d 1249, 2015 U.S. Dist. LEXIS 121078, 2015 WL 5243874 (N.D. Cal. 2015).

Opinion

ORDER GRANTING DEFENDANTS’ ATTORNEY’S FEES MOTIONS AND DENYING DEFENDANT ELI LILY’S UNDERTAKING MOTION

ELIZABETH D. LAPORTE, United States Magistrate Judge

On April 13, 2015, Defendant Eli Lily & Company (“Defendant Eli Lily”) moved for an award of attorney’s fees and for an undertaking to secure any award of attorney’s fees. On April 21, 2015, Defendant Elan Pharmaceuticals, Inc. (“Defendant Elan”) also moved for an award of attorney’s fees. For the reasons set forth below, Defendants’ attorney’s fees motions are GRANTED and Defendant Eh Lily’s undertaking motion is DENIED.

I. RELEVANT FACTUAL BACKGROUND AND PROCEDURAL HISTORY

On February 2, 2010, Plaintiff Alzheimer’s Institute of America, Inc. (“Plaintiff’ or “AIA”) initiated this patent infringement action involving patents related to the “Swedish mutation,” one of the known genetic causes of Alzheimer’s disease. Plaintiff subsequently filed a related case, Alzheimer’s Institute of America, Inc. v. Avid Radiopharmaceuticals, 10-cv-6908 (“Avid ”), in the Eastern District of Pennsylvania. At issue in Avid were patent infringement contentions involving two of the four patents that were at issue in the present case. The Avid court ordered targeted discovery on AIA’s standing and ultimately held a trial on that issue. On December 22, 2011, this Court granted Plaintiffs motion to stay this case pending the outcome of the Avid trial, noting that the outcome “is potentially dispositive of this entire action.” (Dkt. 296 at 4.)

After an eight-day trial, the Avid jury returned a verdict that amounted to a decision that AIA lacked standing to assert the validity of the patents at issue. The Avid court subsequently entered judgment in favor of the defendants and denied AIA’s motion for judgment as a matter of law. Alzheimer’s Inst, of Am., Inc. v. Avid Radiopharmaceuticals, 952 F.Supp.2d 740, 743 (E.D.Pa.2013). That decision was summarily affirmed by the Federal Circuit. Alzheimers Inst, of Am., Inc. v. Avid Radiopharmaceuticals, 560 Fed.Appx. 996 (Fed.Cir.2014).

On March 8, 2012, after the Avid court’s entry of judgment, this Court lifted its stay and dismissed this case for lack of standing, finding that collateral estoppel applied to the Avid jury’s determination. (Dkt. 314 at 2-3.) Subsequently, this Court entered judgment in favor of Defendants. (Dkt. 315.)

On August 20, 2012, this Court entered a stipulation whereby it extended the deadline for Defendants to move for attorney’s fees to 14 days after the entry of an order in Avid disposing of the motions for attorneys’ fees filed by the defendants in that case. (Dkt.324;) On March 30, 2015, the Avid court granted the attorney’s fees motions, finding that the case is exceptional under 35 U.S.C. § 285, and appointed a special master to determine the amount of attorney’s fees to be awarded. The court noted that:

The jury determined that the plaintiff, Alzheimer’s Institute of America, Inc. (“AIA”), was not the owner of the rights to the patent upon which it predicated this infringement action. Instead, it found that the University of South Florida (“USF”) had not waived its ownership rights in the Swedish mutation in[1252]*1252vention. It also found that John Hardy, who was not disclosed on the patent application, was a co-inventor.
The evidence at trial amply showed that Ronald Sexton, AIA’s principal, had conspired with John Hardy and Michael Mullan to defraud USF and Imperial College in London of their ownership rights in the invention. They agreed not to list Hardy as a co-inventor on the patent application. Thus, Mullan was listed as the sole inventor on the patent application and assigned the patent rights to AIA....
To avoid any claim of ownership by USF, Mullan arranged to have the sequencing in an off-campus, private laboratory even though USF had provided Mullan and Hardy a new laboratory dedicated to Alzheimer’s research. Once they had identified the Swedish mutation, Sexton, Hardy and Mullan sought USF’s waiver of any rights in this discovery. They presented a “waiver letter” to USF’s vice-president for research. In their successful effort to obtain his signature on the letter, they led him to believe that the work on the Swedish mutation had been substantially completed while Hardy and Mullan were at Imperial College.
In furtherance of their conspiracy to deprive USF and Imperial College of ownership rights in the invention, Sexton, Hardy and Mullan agreed to omit Hardy’s name from any publication reporting the discovery of the Swedish mutation. They also omitted him as a co-inventor from the patent application.

(Burwell Decl. Ex. 1 (March 30, 2015 Order in Avid) at 2-4.)

II. DEFENDANTS’ ATTORNEY’S FEES MOTIONS

A. Standard

Defendants move for awards of attorney’s fees pursuant to 35 U.S.C § 285, which provides that “[t]he court in exceptional cases may award reasonable attorney fees to the prevailing party.” 35 U.S.C. § 285. Awarding attorney’s fees involves a two-step inquiry: (1) the Court must first determine whether a case is exceptional; and (2) if so, the Court must determine in its discretion whether an award of attorney’s fees is justified. Revolution Eyewear, Inc. v. Aspex Eyewear, Inc., 563 F.3d 1358, 1372-73 (Fed.Cir. 2009). Section “285 commits the determination [of] whether a case is ‘exceptional’ to the discretion of the district court.” Highmark Inc. v. Allcare Health Mgmt. Sys., Inc., — U.S. -, 134 S.Ct. 1744, 1748, 188 L.Ed.2d 829 (2014).

The Supreme Court has held that an “exceptional case”

is simply one that stands out from others with respect to the substantive strength of a party’s litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated. District courts may determine whether a case is “exceptional” in the case-by-case exercise of their discretion, considering the totality of the circumstances. As in the comparable context of the Copyright Act, ‘“[t]here is no precise rule or formula for making these determinations,’ but instead equitable discretion should be exercised ‘in light of the considerations we have identified.’” Fogerty v. Fantasy, Inc., 510 U.S. 517, 534, 114 S.Ct. 1023, 127 L.Ed.2d 455 (1994).

Octane Fitness, LLC v. ICON Health & Fitness, Inc., — U.S. -, 134 S.Ct. 1749, 1756, 188 L.Ed.2d 816 (2014). The Court also noted' that “Section 285 demands a simple discretionary inquiry; it imposes no specific evidentiary burden, much less such a high one. Indeed, patent-infringement litigation has always been [1253]*1253governed by a preponderance of the evidence standard.” Id. at 1758.

B. Discussion

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
128 F. Supp. 3d 1249, 2015 U.S. Dist. LEXIS 121078, 2015 WL 5243874, Counsel Stack Legal Research, https://law.counselstack.com/opinion/alzheimers-institute-of-america-v-eli-lilly-co-cand-2015.